key: cord-0717943-sbx3fit5 authors: Wechselberger, Christian; Süßner, Susanne; Doppler, Stefan; Bernhard, David title: Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients date: 2020-08-11 journal: J Clin Virol DOI: 10.1016/j.jcv.2020.104589 sha: 6b5feeb5fcd9f88e43d6f25840fee8371b72e483 doc_id: 717943 cord_uid: sbx3fit5 BACKGROUND: Serological assays for the determination of the immune status of patients that have tested positive for infection with SARS-CoV-2 by RT-PCR are required for, e.g., contact tracing and epidemiological studies. However, data concerning the performance parameters of commercially available high-throughput ELISA tests are still not available on a large scale. STUDY DESIGN: In our study, we have evaluated an in-house developed ELISA for the detection of the immunoglobulin classes A, G and M directed against the full-length spike glycoprotein from SARS-CoV-2. For this analysis, we have included 110 sera from patients presenting with COVID-19 symptoms or blood donors without symptoms collected at the Austrian Red Cross, Blood Transfusion Service for Upper Austria, Linz. In addition, we have selected four commercially available IgG-based ELISAs as well as one IgA/IgG-based ELISA for the detection of SARS-CoV-2 antigens as well as a multiplexed IgG-based micro-ELISA assay developed for rapid Point of Care testing applications. CONCLUSIONS: All assays evaluated in the course of this study demonstrated suitable sensitivity and specificity values for the identification of patients that have experienced a past infection with SARS-CoV-2. However, testing for the presence of additional immunoglobulins (IgA and IgM) as well as using combinations of different viral antigens is highly advised to improve the predictive values of serological assays. 2 CoV-2. However, testing for the presence of additional immunoglobulins (IgA and IgM) as well as using combinations of different viral antigens is highly advised to improve the predictive values of serological assays. Keywords: SARS-CoV-2; COVID-19; ELISA; Point of Care; Immunoglobulin; Evaluation Background SARS-CoV-2 belongs to the group of beta-coronaviruses and represents the causative agent for coronavirus disease 2019 (COVID- 19) , an acute respiratory disease that emerged in the Chinese province of Wuhan in December 2019 and has since rapidly spread leading to an ongoing pandemic [1, 2] . The gold standard to diagnose an infection with SARS-CoV-2 is reverse transcriptase polymerase chain reaction (RT-PCR) allowing for the identification of asymptomatic carriers as well as patients with an acute infection [3] . While this represents an extremely important step that facilitates curbing the actual spread of the infection, the identification of patients with past episodes of COVID-19 is another cornerstone contributing to the successful handling of the ongoing pandemic and is an area of intensive research [4] [5] [6] . This is especially important in light of the fact that patients that have recovered from a previous SARS-CoV-2 infection might harbor immunoglobulins that could protect them from future infections with this virus, opening also the possibility of using convalescent plasma as a treatment option for COVID-19 patients [7, 8] . Additional aspects during the management of pandemic situations also depend on the information of reliably identifying individuals recovered from COVID-19. Examples include the assessment of herd immunity, strategies to protect vulnerable groups like elderly or people with medical preconditions, or even for pharmacological questions like characterizing antibodies specific for viral antigens exhibiting neutralizing effects that could be used for designing and developing vaccines [9, 10] . This study characterizes the basic performance parameters for an in-house developed ELISA and compares it with five commercially available assays as well as a recently launched microfluidic-chip based, multiplexed micro-ELISA assay designed for rapid Point of Care (POC) testing applications. For this analysis, we have included 110 sera from patients and regular blood donors that presented with J o u r n a l P r e -p r o o f or without COVID-19 symptoms collected at the Austrian Red Cross, Blood Transfusion Service for Upper Austria, Linz. 110 serum samples from patients presenting with COVID-19 symptoms or blood donors without symptoms have been collected at the Austrian Red Cross, Blood Transfusion Service Upper Austria, Linz and written consent was obtained at the time of donation to use sample material also for research purposes (54 male participants with a median age of 44,11 years and 56 female participants with a median age of 43,04 years). Sera of patients with a positive SARS-CoV-2 RT-PCR test result were collected at least 3 week post recovery to ensure enough time to develop a proper immune response. In addition, samples from regular blood donors without the classical COVID-19 symptoms have been obtained to assess possible cross-reactive events that could eventually lead to false positive results. Since there have also been reports on the presence of SARS-CoV-2 RNA in blood and serum samples obtained from infected patients [11] , heat inactivation of the samples in this study has been performed at 56°C for 30 minutes prior to analysis to minimize any residual risk for the laboratory personnel. No heat denaturation was done for the samples used for the Epitope diagnostics and the Abbott Architect ELISA analyses. We have evaluated an in-house developed ELISA (Division of Pathophysiology, Linz, Austria) that GmbH, Germany) and the SARS-CoV-2 IgG ELISA (www.abbott.com, Abbott GmbH, Germany). In addition, we have also included a microfluidic chip based multiplexed micro-ELISA platform for POC testing to detect IgG antibodies against SARS-CoV-2 antigens in this study (www.genspeedbiotech.com, Genspeed Biotech GmbH, Austria). This assay is currently in the process of final certification and will eventually allow for single sample analysis including discrimination of different viral antigens within approximately 15 minutes. In Table 1 the specifications of the respective ELISA kits in terms of immunoglobulin classes used for detection of virus-specific antibodies and the respective SARS-CoV-2 antigens are summarized. For diagnostic tests, the determination of the parameters sensitivity and specificity are usually obtained by comparison with a so-called "gold standard" assay. Since such a clear-cut standard diagnostic test for the characterization of SARS-CoV-2-specific antibodies is still lacking, the evaluation of performance parameters remains challenging. In analogy to previous studies [12, 13] When applying these criteria we have designated 51 patient samples as positive, and 59 samples as negative based on the presence of IgG antibodies, respectively. Subsequently, we have tested the serum samples in parallel for the presence of immunoglobulins specific for the respective SARS-CoV-2 antigens according to instructions of the assay manufacturers (see also Table 1 ). To estimate a potential diagnostic benefit that might arise through the detection of additional Table 2 . The Euroimmun ELISA that we have used offers two immunoglobulin classes for antigen detection (IgA and IgG). When only considering the results of the IgG-based detection, sensitivity and specificity values of 92 and 98% could be achieved. When IgA detection was included in the course of the analysis, these values for the Euroimmun ELISA increased to 96 and 98%, respectively. With our inhouse ELISA we have the capability to detect all three immunoglobulin classes for SARS-CoV-2 antigen detection in parallel (IgA, IgG and IgM). Again, for reason of comparability we have made a first analysis also based solely on IgG-detection and obtained sensitivity and specificity values of 96 and 93%. Naturally, these performance parameters increased for the in-house ELISA when we also J o u r n a l P r e -p r o o f included the detection of the additional immunoglobulins to 97 and 96%, respectively. The data including the results obtained by using additional immunoglobulin classes for the Euroimmun and the in-house ELISA are summarized in Table 3 . However, one has to bear in mind that a diagnostic question aiming at the detection of all immunoglobulin classes in a patient's serum would inevitably lead to a decrease of the performance parameters of the commercial assays solely based on IgGdetection. Another observation that we have made is that in 5 samples analyzed with the Genspeed assay, antibodies exclusively to either the nucleocapsid protein (3 samples) or the full length spike glycoprotein (2 samples) have been detected. This raises the possibility, that a patient is developing an immune response that might very well differ substantially between individuals and assays detecting only a single antigen could lack diagnostic sensitivity. Therefore, the utilization of additional antigens in parallel for COVID-19 detection is another feature that we would certainly encourage for future testing regimes [10, 14] . In Figure 1 Especially in the face of an ongoing pandemic, the rapid development and production of diagnostic kits and devices is a matter of highest importance. It usually requires about 1-2 weeks before immunoglobulins specific for SARS-CoV-2 antigens can be detected in the circulation of a patient after the first viral particles have been encountered by the immune system. The initial immunoglobulins produced during an immune response consist mainly of IgM molecules, whereas IgG antibodies determine the SARS-CoV-2 seroprevalence in the general population (i.e. the long lasting immuno-reactivity usually attributed to herd immunity). Recently published studies indicate that the majority of patients exhibit seroconversion approximately 2-3 weeks after first symptoms were observed and that IgM was shown to decline already about 4 weeks after onset of symptoms whereas IgG levels remained elevated for at least several weeks [16] [17] [18] . The aim of this study was to evaluate the performance of an in-house ELISA designed to detect all three immunoglobulin classes (i.e., IgA, IgG and IgM) with the underlying idea to utilize also the early immunoreactive response to an SARS-CoV-2 infection for diagnostic purposes. We have compared our test to five commercially available serological assays for SARS-CoV-2 as well as a rapid test based on a microfluidic-chip setup. Comparable results were obtained for the commercial assays only detecting IgG. However, the detection of IgM antibodies in case of the in-house ELISA allowed for the identification of six additional samples solely positive for the presence of IgM that would have been missed otherwise. In conclusion, the SARS-CoV-2 serological assays evaluated in the course of this study demonstrated sufficient sensitivity and specificity values for a robust identification of individuals with a previous SARS-CoV-2 infection. However, we have demonstrated that relying only on the detection of the IgG antibody titer for diagnostic purposes led to false negative results in several cases, most likely with J o u r n a l P r e -p r o o f samples obtained during the rather early phases of an immune response. We have shown, that the inclusion of additional immunoglobulin classes further increases the assay sensitivity and should be considered a valuable asset during the selection process of a diagnostic assay, a notion also argued already by others [19, 20] . In addition, also the parallel analysis of more than one SARS-CoV-2 antigen for serological characterization -as demonstrated by the Genspeed COVID-19 assay -might proof beneficial for increasing diagnostic performance. Credit Author Statement CW established the in-house ELISA, performed experiments and wrote the manuscript. All authors designed the study, analyzed the data and contributed in writing the manuscript. A Novel Coronavirus from Patients with Pneumonia in China Epidemiology and clinical features of COVID-19. A review of current literature Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 129 2020 Clinical performance of different SARS-CoV-2 IgG antibody tests Deployment of convalescent plasma for the prevention and treatment of COVID-19 2020 Convalescent Plasma to Treat COVID-19 2020 COVID-19, an emerging coronavirus infection. Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus receptor binding Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerging microbes & infections 9 Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray. bioRxiv : the preprint server for biology PlotsOfData-A web app for visualizing data together with their summaries Profile of specific antibodies to SARS-CoV-2. The first report Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Review of Current Advances in Serologic Testing for COVID-19 COVID-19 Clinical Diagnostics and Testing Technology The authors would like to thank the laboratory teams of the Austrian Red Cross, Blood Transfusion Characteristics of different SARS-CoV-2 assays used in this study.